Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
RécupérationClinique précoce

BPC-157

Recherche publiée et base de preuves

BPC-157 is a synthetic pentadecapeptide derived from a fragment of a protein found in gastric juice. The evidence base is overwhelmingly preclinical: several hundred rodent studies report accelerated healing of tendon, ligament, muscle and gastrointestinal tissue, with mechanisms attributed to angiogenesis, VEGFR2 signalling and nitric oxide system modulation. Peer-reviewed human data are limited to a small number of uncontrolled pilot studies and retrospective case series from a single private clinic, plus one ex vivo study on surgically discarded human arterial tissue; a 2026 preprint, not peer reviewed, describes health records of 1,039 people with documented BPC-157 use. No completed randomised controlled trial and no approved formulation exist, and 2025-2026 systematic reviews in orthopaedic journals explicitly characterise the human evidence as insufficient.

En bref
  • Le BPC-157 est un pentadécapeptide synthétique dérivé d'une protéine gastrique.
  • Des études chez le rongeur ont rapporté une cicatrisation accélérée via VEGFR2.
  • Les données humaines évaluées par des pairs sont des pilotes non contrôlés ; aucun ECR.

18 études · 10 depuis 2023 · plus récente 2026

Études citées
18
Publiées 2023+
10
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • tendon and ligament healing
  • muscle transection and myotendinous junction repair
  • angiogenesis and VEGFR2 signalling
  • nitric oxide system modulation
  • gut barrier and cytoprotection
  • ischemia-reperfusion injury
  • regulatory and anti-doping status

Identifiants du composé

CAS
137525-51-0
PubChem
9941957

Statut réglementaire

Recommandé par un comité consultatif de la FDA.

Le 23–24 July 2026, le comité consultatif sur la préparation pharmaceutique de la FDA a examiné BPC-157 pour la liste 503A Bulks et a recommandé son ajout lors d'un vote rapporté de 8–6 with one abstention. Heard on the first day of the meeting alongside KPV, TB-500 and MOTS-C, and recommended on a divided vote.

Ce n'est pas une approbation. Le comité conseille ; il ne décide pas. La recommandation n'est pas contraignante, la FDA n'a pas terminé la réglementation qui changerait formellement quoi que ce soit, et l'inclusion dans la liste 503A Bulks n'équivaut pas à l'approbation FDA d'un médicament. La liste régit également la préparation pharmaceutique pour les patients, qui est une activité distincte de la fourniture à usage de recherche uniquement.

Ce que le vote consultatif de juillet 2026 a réellement accompli décrit le processus, les autres composés examinés et les quatre choses que le vote est régulièrement mal interprété comme signifiant.

Identité chimique

Ce qu'est BPC-157, chimiquement.

Formule moléculaire
C62H98N16O22
Masse moléculaire
1419.5 g/mol
Numéro CAS
137525-51-0
PubChem CID
9941957

Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.

Les preuves

18 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Revue systématique2025

    Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

    Vasireddi N, et al. · HSS J · systematic review of the BPC-157 literature from an orthopaedic sports medicine perspective

    The authors synthesised preclinical evidence for healing of fractures, tendon ruptures, ligament tears and muscle injuries, and noted that BPC-157 lacks FDA approval and is banned in professional sport despite increasing clinical and athlete use.

  2. 02Clinique humaine2026

    Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes

    Venkatakrishnan A, et al. · Preprints.org · preprint, not peer reviewed; retrospective cohort built from de-identified clinical notes in a U.S. federated health-records network, 1,039 patients with documented BPC-157 use, 2020-2026, curated by a large language model with physician validation

    Improvement in pain, wound or tissue healing or function was documented in 79% of 354 users with a recorded response direction and worsening in 5%, with direction unavailable for 685 users. Half of users co-used other agents, including TB-500 (12.9%), and the authors stated the notes cannot establish efficacy or separate BPC-157 effects from co-treatments, placebo effects or reporting bias.

    Résultat de sécurité signalé. Neuropsychiatric (1.4%), injection-site hypersensitivity (1.4%) and gastrointestinal (1.3%) adverse events were documented during use and were likely under-reported.

  3. 03Clinique humaine2025

    Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

    Lee E, et al. · Altern Ther Health Med · uncontrolled open-label pilot; 2 adults, intravenous BPC-157 10 mg on day 1 and 20 mg on day 2 in 250 cc saline over 1 hour

    Infusions of up to 20 mg produced no measurable changes in cardiac, liver, kidney, thyroid or blood glucose biomarkers and no reported side effects in the two participants. The authors stated that larger studies are needed to confirm safety.

  4. 04Clinique humaine2024

    Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study

    Lee E, et al. · Altern Ther Health Med · uncontrolled open-label pilot; 12 women aged 39-76 who had not responded to pentosan polysulfate, single cystoscopic injection of 10 mg BPC-157 around the inflamed bladder area

    Ten of twelve patients reported complete resolution of symptoms on the Global Response Assessment questionnaire and the remaining two reported approximately 80 percent improvement, with no reported adverse events. The study had no control group and no blinding.

  5. 05Clinique humaine2021

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B · Altern Ther Health Med · retrospective single-clinic chart review 2019-2020; 17 patients receiving intra-articular BPC 157 alone or combined with thymosin beta-4, 16 reached by telephone follow-up

    Patients self-rated pain before injection and the degree and duration of relief afterwards. No validated instruments for function, stiffness, quality of life or activities of daily living were used, and there was no control group.

  6. 06Animal in vivo2026

    Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

    Biçer O, et al. · Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats, 4 groups of 8 (control, BPC-157 10 ug/kg/day, TB-500 60 ug/kg/day, combination), intraperitoneal, 4 weeks

    Both peptides were associated with improved histopathological scores and extracellular matrix organisation at four weeks, and the TB-500 group additionally showed a significantly higher maximum load to failure. Combined BPC-157 and TB-500 treatment did not confer additional benefit over either agent alone.

  7. 07Animal in vivo2026

    Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury

    Yildirim AK, et al. · Sci Rep · rat hind-limb ischemia-reperfusion by abdominal aortic clamping (45 min ischemia, 2 h reperfusion); 24 male Wistar albino rats in 4 groups of 6

    BPC 157 administration was associated with reduced markers of oxidative stress, inflammation and apoptosis in the reperfused limb tissue compared with untreated ischemia-reperfusion controls.

  8. 08Animal in vivo2025

    Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats

    Matek D, et al. · Pharmaceutics · rat model of complete (rectus) and partial (vastus) quadriceps muscle detachment from bone; per-oral BPC 157 at 10 ug/kg and 10 ng/kg daily, assessed to day 28

    Per-oral BPC 157 was reported to produce muscle-to-bone reattachment and restoration of function after both complete and partial quadriceps detachment, compared with non-healing in untreated animals.

  9. 09Animal in vivo2022

    Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs

    He L, et al. · Front Pharmacol · rats and dogs; single intravenous dose, single intramuscular doses at three ascending levels, and repeated intramuscular administration

    The study characterised elimination half-life, tissue distribution, metabolism and excretion of BPC157 in two species, providing the pharmacokinetic groundwork the compound otherwise lacks.

  10. 10Animal in vivo2021

    Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

    Japjec M, et al. · Biomedicines · rat quadriceps tendon dissected from the quadriceps muscle, a myotendinous junction defect that does not heal spontaneously; BPC 157 10 ug/kg and 10 ng/kg intraperitoneally and per-orally

    Treated animals showed improved macroscopic, microscopic, biomechanical and functional outcomes at the myotendinous junction, accompanied by changes in eNOS and COX-2 mRNA levels and in oxidative stress and nitric oxide levels.

  11. 11Animal in vivo2020

    Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds.

    Xu C, et al. · Regul Toxicol Pharmacol · preclinical toxicology programme: single and repeated dose in mice, rats, rabbits and dogs, plus local tolerance, genotoxicity and embryo-fetal studies

    No test-related effects were seen in single-dose studies; repeated dosing was well tolerated in dogs apart from a reversible creatinine decrease at the highest dose; irritation was mild and no genetic or embryo-fetal toxicity was observed.

    Résultat de sécurité signalé. Repeated dosing in dogs produced a reversible decrease in creatinine at the highest dose; no other toxicity was reported across four species.

  12. 12Animal in vivo2017

    Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation

    Hsieh MJ, et al. · J Mol Med (Berl) · chick chorioallantoic membrane assay, endothelial tube formation assay, and rat hind-limb ischemia with laser Doppler flow measurement

    BPC 157 increased vessel density in vivo and in vitro and accelerated recovery of blood flow in ischemic rat hind limb. The pro-angiogenic effect was associated with VEGFR2 activation and upregulation.

  13. 13Animal in vivo2010

    Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat

    Cerovecki T, et al. · J Orthop Res · rat medial collateral ligament transection followed 90 days, with intraperitoneal, per-oral (drinking water) and topical peptide administration given without a carrier

    BPC 157 improved medial collateral ligament healing across all three routes of administration over 90 days after surgical transection.

  14. 14Animal in vivo2006

    Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157

    Staresinic M, et al. · J Orthop Res · complete transverse transection of rat quadriceps muscle 1.0 cm proximal to the patella, with systemic BPC 157 given without a carrier

    Systemic BPC 157 induced healing of the completely transected quadriceps muscle and maintained that healing with functional restoration, whereas the untreated defect persisted. This is one of the foundational muscle-injury papers.

  15. 15In vitro2026

    Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery

    Yildirim AK, et al. · J Clin Med · ex vivo human internal mammary artery rings from elective CABG surgery; n=12 segments, endothelium-intact and denuded, with and without L-NAME

    BPC 157 produced a concentration-dependent reduction in phenylephrine-induced contraction, significantly greater in endothelium-intact rings. NOS inhibition with L-NAME attenuated the relaxation and largely abolished the endothelium-dependent advantage.

  16. 16In vitro2011

    The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

    Chang CH, et al. · J Appl Physiol (1985) · rat tendon explant outgrowth cultures and isolated tendon fibroblasts cultured with or without BPC 157

    BPC 157 significantly accelerated the outgrowth of tendon fibroblasts from explants and increased fibroblast survival and migration. This is one of the foundational mechanistic papers for the tendon-healing claim.

  17. 17Revue2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, et al. · Sports Med · narrative review covering AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, Tb4 and TB-500

    The review reported that many unapproved peptides show favourable tissue repair and metabolic outcomes in animal models, but that rigorous human safety data are scarce. It also discussed the placebo effect and social media amplification as mediators of perceived peptide efficacy.

  18. 18Revue2026

    Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.

    Moiz A, et al. · Mo Med · narrative clinical review of unregulated injectable peptides

    Classified BPC-157, TB-500 and melanotan-II as unapproved peptides without established human safety profiles and listed risks including contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis and carcinogenesis.

    Résultat de sécurité signalé. Authors flagged product contamination, impurities and theoretical angiogenesis/carcinogenesis risk for unregulated BPC-157.

Limites

Ce que ces preuves n'établissent pas.

There is no completed randomised, placebo-controlled human trial of BPC-157 for any indication, no established human dose, and no long-term human safety data; the only peer-reviewed human reports are two uncontrolled pilot studies and one retrospective chart review, all from the same private clinic, and the one larger observational dataset is a health-records preprint that has not been peer reviewed. Much of the preclinical corpus originates from a small number of closely affiliated research groups, which limits independent replication.

Questions courantes sur la recherche.

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide fragment derived from a protective protein found in human gastric juice. It is one of the most widely studied compounds in preclinical tissue-repair research.

How does BPC-157 differ from TB-500?

Both appear in tissue-repair research, but they are unrelated molecules. BPC-157 is a gastric-juice-derived pentadecapeptide studied for tendon, ligament, and gut models; TB-500 is a synthetic fragment of thymosin beta-4 studied for actin regulation and cell migration. The two are frequently co-studied, which is why combined vials exist.

How long does BPC-157 stay in the body?

The only published pharmacokinetic characterisation of BPC-157 is a 2022 study in rats and dogs, which measured elimination half-life, tissue distribution, metabolism and excretion after a single intravenous dose, single intramuscular doses at three ascending levels, and repeated intramuscular administration. No equivalent human pharmacokinetic study has been published. The peer-reviewed human record consists of two uncontrolled pilot studies and one retrospective chart review, none of which characterised the peptide's disposition.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.